360 related articles for article (PubMed ID: 25459181)
1. Stem cell transplantation in Hodgkin lymphoma.
Reddy NM; Perales MA
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1097-112. PubMed ID: 25459181
[TBL] [Abstract][Full Text] [Related]
2. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
3. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
4. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
5. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
6. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
[TBL] [Abstract][Full Text] [Related]
7. Managing relapsed and refractory Hodgkin lymphoma.
Brice P
Br J Haematol; 2008 Apr; 141(1):3-13. PubMed ID: 18279457
[TBL] [Abstract][Full Text] [Related]
8. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
9. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center].
Trnĕný M; Vacková B; Pytlík R; Cieslar P; Válková V; Gasová Z; Kobylka P; Trnková M; Krejcová H; Klener P
Cas Lek Cesk; 2006; 145(1):19-24. PubMed ID: 16468237
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
11. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A
Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
13. Therapy of relapsed Hodgkin lymphoma.
Cashen AF; Bartlett NL
Blood Rev; 2007 Sep; 21(5):233-43. PubMed ID: 17683834
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
15. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
[TBL] [Abstract][Full Text] [Related]
17. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
Moskowitz AJ; Perales MA; Kewalramani T; Yahalom J; Castro-Malaspina H; Zhang Z; Vanak J; Zelenetz AD; Moskowitz CH
Br J Haematol; 2009 Jul; 146(2):158-63. PubMed ID: 19438504
[TBL] [Abstract][Full Text] [Related]
18. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
Bentolila G; Pavlovsky A
Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
20. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
